Small Cell Carcinoma of the Ovary, Hypercalcemic Type, in a 12-Month-Old Girl

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a highly aggressive malignant tumor affecting predominantly young adults and adolescents with an average age of 23.9 at time of diagnosis. Up to two thirds of patients have paraneoplastic hypercalcemia. The molecular signature of these tumors is SMARCA4 mutations, with somatic and germline pathogenic variants previously described. We report a case of a previously healthy one-year-old girl who was noticed to have mild anemia and an abdominal mass during a well-child visit. Further laboratory testing revealed hypercalcemia. A computerized tomography scan showed a left-sided ovarian mass (9.3 x 7.3 x 7 cm). The resection specimen showed a large ovarian tumor with solid tan-yellow cut surfaces and small foci of necrosis. Microscopically, the tumor was composed of sheets of small, hyperchromatic epithelioid cells with focal rhabdoid large cell morphology. The tumor cells were strongly and diffusely positive for WT1 (N-terminal antibodies) with focal EMA and Pan-keratin positivity. Absent SMARCA4 (BRG1) protein expression by immunohistochemistry ultimately established the diagnosis of small cell carcinoma of the ovary, hypercalcemic type. To our knowledge, this is the youngest patient reported in the literature.

[1]  J. Trent,et al.  Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines , 2020, Clinical Cancer Research.

[2]  Bingjian Lu,et al.  An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings , 2019, Journal of Cancer.

[3]  M. Frey,et al.  Small Cell Carcinoma of the Ovary: A Rare Tumor With a Poor Prognosis , 2018, International Journal of Gynecologic Cancer.

[4]  J. Trent,et al.  The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type , 2017, The Journal of pathology.

[5]  W. Foulkes,et al.  Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small‐cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics , 2016, Histopathology.

[6]  R. Siebert,et al.  Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type , 2014, Nature Genetics.

[7]  R. Tambouret,et al.  Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass. , 2010, The New England journal of medicine.

[8]  E. Oliva,et al.  An Immunohistochemical Analysis of Ovarian Small Cell Carcinoma of Hypercalcemic Type , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[9]  S. Florell,et al.  Ovarian small cell carcinoma of the hypercalcemic type in a 14 month old: the youngest reported case. , 1999, Medical and pediatric oncology.

[10]  E. Oliva,et al.  Small Cell Carcinoma of the Ovary, Hypercalcemic Type: A Clinicopathological Analysis of 150 Cases , 1994, The American journal of surgical pathology.

[11]  R. Scully,et al.  Human parathyroid hormone‐related protein in ovarian small cell carcinoma. An immunohistochemical study , 1994, Cancer.

[12]  R. Scully,et al.  Small cell carcinoma of the ovary with hypercalcemia: A report of eleven cases , 1982, Cancer.